Divergent Capital 7651
14 articles covering 11 companies
Q1'26 Idea Inventory, Part 1: $CPH.TO, $RCI.B, $SNAP, $HON.
• 2026-02-18T05:22:24.868+00:00
Allison Transmission (ALSN) & Dana Inc (DAN) Merger: A Merger Opportunity with Low Deal Risk
• 2025-11-24T02:32:33.791+00:00
GCI Liberty: A Spin-Off Opportunity with Multiple Catalysts
• 2025-07-11T02:46:17.618+00:00
Notes from Cipher Pharmaceuticals' Planet Microcap Interview dated 21 August 2024.
• 2024-08-22T07:12:04.003+00:00
Estimate of Cipher Pharmaceuticals' Potential Future Operating Income Post-Natroba Acquisition.
• 2024-08-12T06:12:42.092+00:00
Initial Thoughts on Cipher's Acquisition of ParaPRO's, "Natroba"
• 2024-08-01T03:20:15.32+00:00
Haypp Group AB: A Fly-Wheel Business Surfing the Nicotine Pouch Tidal Wave, Positioned to Thrive Amidst Intense Competition
• 2024-07-09T11:03:14.818+00:00
Haypp Group AB: Write-Up Preview
• 2024-07-04T23:27:46.101+00:00
BQE Water: A Capital-Light Compounder with Expanding Margins and Long-Term Recurring Revenues
• 2024-06-01T00:07:33.133+00:00
BQE Water: Write-Up Preview
• 2024-05-30T09:40:28.167+00:00
Moberg Pharma AB: A Royalty on an Innovative Treatment for a Condition Affecting Hundreds of Millions of People Globally
• 2024-05-24T01:48:18.835+00:00
Cipher Pharmaceuticals: A High ROIC Legacy Business at a Fair Price with a Free Call-Option on Two Unpriced Catalysts
• 2024-05-19T23:17:37.185+00:00
Cipher Pharmaceuticals: Write-Up Preview
• 2024-05-13T02:44:45.553+00:00
Moberg Pharma AB: Write-Up Preview
• 2024-05-09T01:53:06.992+00:00